April 23, 2024 11:49 (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Rajnath Singh visits Siachen, carries out assessment of security situation | Government employee shot dead in targeted attack in Kashmir's Rajouri | 'Congress will take away your homes, jewels': PM Modi ups his attack amid row | Centre orders sampling test of spices from Everest, MDH after ban in Hong Kong, Singapore | 'Illegal, I challenge it': Mamata Banerjee on Calcutta HC cancelling 24,000 jobs in SSC scam probe
Argentine scientists say one dose of Russia's Sputnik V develops high immune response Sputnik V
Wallpaper Cave

Argentine scientists say one dose of Russia's Sputnik V develops high immune response

India Blooms News Service | @indiablooms | 14 Apr 2021, 09:08 am

Moscow/Sputnik: The Russian COVID-19 vaccine Sputnik V prompts a high immune response even with a single dose, a study by Argentine scientists and cited by the country's government on Tuesday, has shown.

Last month, the Argentine government decided to delay second doses of vaccines in a bid to offset the shortages in drugs against the COVID-19 disease across the world.

"A global analysis of the immune response induced by the Sputnik V vaccine, in which 288 individuals participated, indicates that 94% showed the presence of specific antibodies after receiving a single dose," the government said, citing the study.

Notably, 61 participants were previously infected with COVID-19. According to the study, they had 4.6 times more antibodies after the Russian vaccine shot than the rest of the group.

The study also revealed that 96 percent of people under 60 developed antibodies within 21 days after getting vaccinated. The rate stands at 89 percent among those aged over 60.
After two doses of Sputnik V, 100 percent of immunized people have antibodies, the study also noted.

Sputnik V has so far been approved for use in 60 states across the world. According to phase 3 trial results published in The Lancet medical journal, the vaccine has 91.6 percent efficacy against symptomatic COVID-19.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.